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Introduction: A major problem in cartilage repair is the lack of chondrogenic cells migrating from healthy
tissue into defects. Cartilage is essentially avascular and therefore its healing is not considered to involve
mononuclear cells. Peripheral blood derived mononuclear cells (PBMC) offer a readily available autologous cell
source for clinical use and therefore this study was designed to evaluate the effects of PBMCs on
chondrocytes and cartilage.
Methods: Human primary chondrocytes and cartilage tissue explants were taken from patients undergoing total
knee replacement (n = 17). Peripheral blood samples were obtained from healthy volunteers (n = 12) and mononuclear
cells were isolated by density-gradient centrifugation. Cell migration and chemokinetic potential were measured using a
scratch assay, xCELLigence and CyQuant assay. PCR array and quantitative PCR was used to evaluate mRNA expression
of 87 cell motility and/or chondrogenic genes.
Results: The chondrocyte migration rate was 2.6 times higher at 3 hour time point (p < 0.0001) and total number
of migrating chondrocytes was 9.7 times higher (p < 0.0001) after three day indirect PBMC stimulus and 8.2 times
higher (p < 0.0001) after three day direct co-culture with PBMCs. A cartilage explant model confirmed that PBMCs
also exert a chemokinetic role on ex vivo tissue. PBMC stimulation was found to significantly upregulate the mRNA
levels of 2 chondrogenic genes; collagen type II (COL2A1 600–fold, p < 0.0001) and SRY box 9 (SOX9 30–fold,
p < 0.0001) and the mRNA levels of 7 genes central in cell motility and migration were differentially regulated by
24h PBMC stimulation.
Conclusion: The results support the concept that PBMC treatment enhances chondrocyte migration without
suppressing the chondrogenic phenotype possibly via mechanistic pathways involving MMP9 and IGF1. In the
future, peripheral blood mononuclear cells could be used as an autologous point-ofcare treatment to attract
native chondrocytes from the diseased tissue to aid in cartilage repair.Introduction
The overarching goal of repairing articular cartilage
lesions is to achieve a functional and viable joint sur-
face in the long term and prevent progression to
osteoarthritis (OA) [1, 2]. Defects in adult articular
cartilage that do not penetrate the underlying vascu-
larized tissues generally do not heal [3]. Unlike the
majority of tissues, cartilage healing does not involve* Correspondence: niina.hopper@gmail.com
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Another issue in cartilage repair is the lack of chon-
drogenic cells migrating from healthy tissue into local
defects. Dogma suggests that chondrocytes in adult
cartilage do not migrate in their native environment
due to the surrounding highly tensile collagen net-
work resulting in a highly pressurized matrix [4].
However, chondrocyte motility has been reported by a
small number of publications [5, 6] which observed
that after bovine articular cartilage was injured by
blunt impact the defect area was repopulated withinrticle distributed under the terms of the Creative Commons Attribution License
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surrounding matrix.
During our previous studies using explants derived
from human osteoarthritic articular cartilage cultured in
serum-free conditions we have observed the formation
of cell monolayers around the explants after 7–10 days
in culture [7]. This evidence suggests that human chon-
drocytes are capable of substantial migration and this ac-
tion is likely to be initiated either by pre-existing OA
damage or by cutting the tissue. The functional role of
the migratory cells is not clearly understood [8]. In the
study by Seol et al., [6] migratory cells harvested from
the cartilage injury area produced more side populations
identified by flow cytometry, and expressed lower levels
of cartilage extracellular matrix (ECM) genes, such as col-
lagen type II and aggrecan, compared with normal chon-
drocytes. The migratory cells are thus proliferative and
exhibit a phenotype different from chondrocytes [8].
The majority of chondrocyte migration studies in the
literature have been conducted by following isolated cell
movements on planar surfaces in vitro, but there is also
some evidence of ex vivo cell migration from cartilage.
Human cartilage explant studies raise the intriguing
possibility that matrix injuries resulting in disruption of
the collagen network of adult cartilage by extensive cut-
ting [9], collagenase digestion [10] or defect drilling [11]
could provide a permissive environment for chondrocyte
motility.
Growth factors have previously been reported to enhance
current cartilage repair techniques via multiple mecha-
nisms including 1) recruitment of chondrogenic cells
(chemotaxis), 2) stimulation of chondrogenic cell prolif-
eration (mitogenesis) and 3) enhancement of cartilage
matrix synthesis. Growth factors and cytokines circulate
in the peripheral blood and reach articular cartilage
through the synovial fluid and several have been pro-
posed to influence chemotaxis in cartilage repair including
fibroblast growth factor (FGF), platelet-derived growth
factor (PDGF), vascular endothelial growth factor (VEGF),
insulin-like growth factor (IGF)1, IL8, bone morphogenic
protein (BMP)4, BMP7, transforming growth factor (TGF)β
and stromal-derived factor (SDF)1 [12–17]. Traumatized
cartilage releases chemoattractive factors for chondrogenic
progenitor cells such; PDGF and IGF1, which are known to
induce a significant site-directed migratory response [15].
However, at the same time IL1β and TNFα are released
and these chemokines inhibit migratory activity which
might contribute to the low regenerative potential of
cartilage in vivo.
Whilst articular cartilage defects have a limited capacity
to repair, cartilage injuries that penetrate the subchondral
bone can repair. Shapiro et al. [18] showed that this repair
is mediated by the proliferation of cells that invade the de-
fect from the underlying bone marrow and vasculature.This physiological repair response still forms the rationale
behind a number of orthopaedic procedures described as
bone marrow stimulation techniques [19, 20]. However,
whilst this repair capacity is usually attributed to the re-
cruitment of mesenchymal stem cells from the bone mar-
row or vascular pool, little is known of the contribution of
other blood cells to the healing process. One cell type that
may be involved is the peripheral blood mononuclear cell
(PBMC). These cells can secrete a large number of cyto-
kines [21, 22] and thus, could produce chemoattractants
to assist in cartilage repair. Secretome of PBMCs has been
previously analysed and reported to enhance wound heal-
ing in a mouse model [23]. In addition, articular cartilage
regeneration has been reported in the clinics with PBMC
therapy using intra-articular injections of autologous
PBMCs in combination with hyaluronic acid (HA) in a
clinical case study of 5 patients [24] and in a randomized
controlled trial of 180 patients [25], with good clinical
outcomes.
The aim of this study was to observe whether PBMCs
enhance chondrocyte migration without adversely effect-
ing chondrogenicity in order to establish if PBMCs have
potential in therapeutic cartilage repair.
Methods
Tissues
Human tissue was obtained with full ethical consent in
writing to participate in the study from all patients under-
going total knee replacement for osteoarthritis (Cambridge
Local Research Ethics Committee No. 06/Q0108/213). The
articular cartilage showed characteristic features of OA
histopathology, with disruption and fibrillation of the
articular surface; however, for the experiments only macro-
scopically normal-looking cartilage tissue was used. Articu-
lar cartilage was harvested from a total of 17 consecutive
patients (average age 71.8 ± 7.7 years) from the femoral
condyles and tibial plateau using a sterile scalpel blade and
diced as finely as possible.
Mesenchymal stromal cells (MSC) were isolated from
the infrapatellar fat pad of seven consecutive human
donors (average age 71.4 ± 8.3 years). The infrapatellar
fat pad was minced using a sterile scalpel blade and
placed in medium containing 10 % heat inactivated FBS,
penicillin/streptomycin (100 IU/ml and 100 μg/ml), genta-
mycin (10 ng/ml) and amphotericin B (2.5 μg/ml).
Primary cell isolation
1. Collagenase digestion: chondrocytes and MSCs were
released from the tissue using 0.2 μm filter-sterilized
Collagenase A (11088793001, Roche, UK) 0.2 % w/v in Dul-
becco’s modified Eagle’s medium containing 10 % heat
inactivated FBS, penicillin/streptomycin (100 IU/ml and
100 mg/ml), gentamicin (10 ng/ml) and amphotericin B
(Fungizone™ - 2.5 μg/ml) (complete medium). For standard
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plastic at a density of 20,000 cells/cm2 and used at passage
3 or less.
2. Explant outgrowth: full-depth slices of articular cartil-
age were incubated in medium as above in 6-well plates.
Cells were allowed to migrate out of the tissue to form
monolayers at which point the explants were removed and
the cells trypsinised before use in experiments at the same
passage number as those derived by collagenase digestion.
Blood samples
Peripheral blood samples were taken from 12 young (32.9 ±
9.3 years) healthy volunteers using a sterile Monovette
EDTA 9-ml tube. The blood was diluted 1:1 with Hank’s
balanced salt solution, layered on Lymphoprep™ solutionFig. 1 Schematic illustration of migration studies. a Scratch assay, b Boyde
demonstrating the position of cartilage explant and chondrocytes in relatio(Axis-Shield, Dundee, Scotland) and centrifuged for 20
minutes at 800 g. The mononuclear cell-rich band was
removed, and resuspended in medium supplemented with
10 % FBS and the cells pelleted by centrifugation for 10
minutes at 250 g.
Cell migration
Scratch assay
In the scratch assay [26] primary chondrocytes were
grown to confluence in a 24-well plate. A thin wound
(800 μm) was introduced by scratching the cell monolayer
with a sterile pipette tip. Two test groups were compared: 1)
chondrocytes alone and 2) chondrocytes together with
PBMCs (1:1) to test direct cell-to-cell contact (Fig. 1a).
The migration of cells from the wound edge into then chamber with chondrocytes and c Boyden chamber with explants
n to peripheral blood mononuclear cells (PBMCs)
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an Eclipse Ti Nikon microscope and the distance of the
gap was measured at three time points and analysed with
Nikon Advanced Research Elements 3.21.00 software.
xCELLigence assay
The migration and chemokinetic potential of the cells was
measured using an xCELLigence System RTCA DP real-
time cell analyser fitted with CIM plates (05665817001,
Roche, UK), which is based on the Boyden chamber model
[27]. The CIM plates have 16-well migration units com-
prising upper and lower chambers separated by a porous
(pore size 8 μm) polyethylene terephthalate (PET) mem-
brane in conjunction with microelectrodes. Cell migration
(2.0 × 104) was measured with the presence of complete
medium but containing 1 % FBS.
In the xCELLigence assay, three test groups were used:
1) chondrocytes in the upper chamber alone (control)
and 1 % FBS in the lower chamber, 2) chondrocytes in
the upper chamber and +PBMC (as presented on Fig. 1)
(1:1) in the lower chamber to test directed cell move-
ment without cell-to-cell contact, 3) chondrocytes in the
upper chamber and #PBMC (as presented on Fig. 1) (1:1)
together in the upper chamber to test direct cell-to-cell
contact effect (Fig. 1b). As a negative control PBMCs in
the upper chamber with 1 % FBS in the lower chamber
was also recorded. Each experiment was done with four
replicates and after equilibration, the analyser was pro-
grammed to scan the membrane every 15 minutes. As the
half-life of a circulating monocyte has been estimated
to be around 3 days in humans the data analysis was
performed over 3 days [28, 29].
A similar experimental design was used to analyse if cells
can be stimulated to migrate from native human articular
cartilage by PBMCs. Full-thickness human articular cartil-
age explants were prepared 5 days prior to the migration
experiment with a 5-mm biopsy punch (Brymill Cryogenic
Systems) and cultured in complete cell culture medium.
Explants were then transferred to the xCELLigence system
under the same conditions as those used for isolated chon-
drocytes (Fig. 1). The total number of cells migrating was
quantified at the end of the study using a cell index (CI)
value. CI values are based on impedance measurements
providing quantitative information about cell migration
through the pores of the membrane. The cell migration
rate was measured from the slope of the graph.
Cell proliferation
In the CyQUANT assay 5 × 104 cells (n = 5) were seeded
per well in triplicate in 48-well plates and grown until
almost confluent. Following confluence a thin wound
(800 μm) was introduced by scratching the cell mono-
layer with a sterile pipette tip. The cells were stimulated
with PBMCs for 24 h, then washed and frozen at −20 °C. Thetotal DNA was quantified using the manufacturer’s instruc-
tions (CyQUANT, Thermo Fisher Scientific, Loughborough,
UK). Fluorescence (excitation 480 nm, emission 520 nm) was
measured on a FLUOstar OPTIMAmicroplate reader. Simi-
larly, a DNA standard curve was created by diluting lambda
DNA in 1 × CyQUANT buffer to give a range covering 1 to
10 ng of DNA in 100 μl of buffer. The standards were also
processed and treated similarly to the test samples.
Cell activity and biosynthesis
Trypan blue exclusion assay was used to determine the
PBMC viability in culture at days 1 and 3. In addition,
human cytokine array (Proteome Profiler Array, ARY005,
R&D Systems, Abingdon, UK) was used to measure the
presence of 36 human cytokines secreted by PBMCs in
culture at day 3.
mRNA expression
Digested chondrocytes were cultured with or without non-
adherent PBMCs (1:1) for 24 h. After stimulation the
PBMC’s were washed away to avoid mRNA from the
mononuclear cells in suspension. Chondrocyte mRNA was
extracted using TRIzol® reagent (15596–026, Ambion,
Paisley, UK) according to the manufacturer’s instructions.
The RNA pellet was air-dried and resuspended in 35 μl
DNAse/RNAse-free water subsequently, RNA concentration
and quality were checked with optical density (OD) 260/280
measurement using a NanoDrop spectrophotometer. Qual-
ity was verified by 1.2 % agarose gel electrophoresis using
the FlashGel® System (57067, Lonza, Nottingham, UK)
and RNA Cassettes (57027, Lonza, Nottingham, UK).
PCR array
cDNA synthesis was performed with RT2 First Strand kit
(330401, Qiagen, Manchester, UK) following the manufac-
turer’s instructions using 540 ng RNA. Human Cell Motility
PCR Array (PAHS-128ZA-2, Qiagen, Manchester, UK) was
used to identify and compare 84 key genes central to cell
movement. A Stratagene Mx3000P® real-time cycler was
programmed with HotStart DNA Taq Polymerase activa-
tion for 10 minutes at 95 °C and then 40 cycles of 1) de-
naturation for 15 s at 95 °C and 2) combined annealing/
extension for 1 min at 60 °C. The data acquisition was per-
formed during the combined annealing/extension step and
the results analysed with RT2 Profiler PCR Array Data Ana-
lysis software version 3.5 using the Δ cycle threshold (ΔCt)
method and normalised to the mean of five housekeeping
genes used (B2M, HPRT1, RPL13A, GAPDH and ACTB).
Quantitative real-time PCR (rtPCR)
Complementary DNA synthesis was performed with Super-
Script® VILO™ kit (11754–050, Invitrogen, Paisley, UK) fol-
lowing the manufacturer’s instructions using 2.5 μg RNA.
The real-time quantitative PCR reaction was prepared using
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Manchester, UK) together with QuantiTect Primer Assay
(Hs_COL2A1_1_SG, Hs_SOX9_1_SG and Hs_IGF1_1_SG)
using 50 ng template cDNA on a Stratagene Mx3000P®
real-time cycler. The relative copy numbers of target
genes were calculated from the standard curve for each
gene and normalised to the housekeeping gene, beta-2
microglobulin (Hs_B2M_1_SG). The MMP9 mRNA expres-
sion was measured with TaqMan® assay (Hs00234579_m1)
according to manufacturer’s instructions using the
StepOnePlus™ real-time PCR system.Statistical analysis
All samples were collected in four replicates and the data
are presented as the mean ± standard deviation (SD) with
the significance level set at 0.05. The data were evaluated
using Student’s t test to determine statistically significant
differences with GraphPad Prism 5 software.Results
PBMC stimulation
Migration of isolated chondrocytes
The addition of PBMCs significantly increased chondro-
cyte motility in both migration assays (Fig. 2). A scratch
assay was used to measure chondrocyte migration in a
direct cell-to-cell contact model. At 24 h, the scratch
width in untreated chondrocyte cultures was reduced by
51 %, whereas with the chondrocytes cultured with
PBMCs, it was reduced by 84 % (p = 0.002) (Fig. 2a). In
addition, the wound closure rate at the 3 h time point
was significantly higher (p = 0.0009) with chondrocytes
cultured with PBMCs (31.5 μm/h) compared to without
PBMCs (14.1 μm/h) (Fig. 2b).
To investigate further the direct and indirect effects of
PBMCs on chondrocyte migration, a Boyden chamber
model was used. In the first 3 h the cell migration rate
was highest and the chondrocyte migration peaked at
48 h (Fig. 2c). At the end of the experiment (70 h), the
total number of migrating chondrocytes was significantly
9.7-fold higher in the indirect combination with PBMCs
(p <0.0001) than the negative control (chondrocytes
cultured without PBMCs) (Fig. 2d). Chondrocytes in
the direct cell-to-cell model increased the migration
8.2-fold (p <0.0001).
Total cell migration was compared between chondrocytes
and adipose-tissue-derived stromal cells (MSC). MSCs
are reported to have very high motility as compared to
other adult non-carcinogenic cell types [30]. We have
previously shown that the migration of MCSs is also re-
sponsive to PBMC stimuli [31] and in this study MSC
total cell migration was 37 % higher than that of chon-
drocytes (p = 0.002, Fig. 2e).Migration from cartilage explants
In the cartilage explant study the total amount of cells
migrating at day 3 was highest in the co-culture model
(# as presented on Fig. 2) a 17.1-fold increase (p = 0.001)
compared to the control and was increased 2.1-fold in the
indirect culture model (+ as presented on Fig. 2) (Fig. 2f).
However, the initial cell migration rate from cartilage
tissue explant measured during the first 3 h was 2.6-fold
higher when explants were cultured indirectly with
PBMCs (p <0.0001) and 1.5-fold higher (p = 0.0002) in
a direct co-culture compared to the control (Fig. 2g). In
the second negative control (PBMCs in the upper cham-
ber with 1 % FBS in the lower chamber) the xCELLigence
system did not detect cells with a radius <8 μm and there-
fore the cells from peripheral blood did not affect the cell
index read-out (data not shown).
Cell proliferation
In order to evaluate the contribution of cell proliferation
to the observed cellular migration, the total DNA was mea-
sured in the scratch assay in order to indirectly quantify
cell proliferation (Fig. 3a). The scratch lowered the total
DNA by 15 % compared to the confluent control well
(total 3.0 ng). There was no significant difference between
the PBMC-stimulated and non-stimulated test groups
(n = 5) in the total DNA amount in either in the control
or scratch test group, with −22 % and −23 %, respectively.
Cell activity and biosynthesis
The cell viability assay demonstrated that 95.4 ± 2.3 % of
PBMCs were live in culture at day 1 and 92.2 ± 3.0 % at
day 3. In addition, the PBMCs were found to be biosyn-
thetically active secreting 15 different chemokines (C5a,
CXCL1, ICAM-1, IL-1β, IL-1ra, IL-6, IL-8, IL-13, IL-16,
CXCL10, CXCL11, CCL2, MIF, CCL5, PAI-1) at day 3 in
culture (data not shown).
Quantitative PCR (qPCR)
In order to verify that the migrating cells were maintain-
ing their chondrocyte phenotype and not acquiring a fi-
broblastic phenotype, qPCR was used to measure two
key chondrogenic genes (SOX9 and COL2A1). The mRNA
levels for these genes was upregulated by the 24 h PBMC
stimulus; SOX9 (30-fold, p <0.0001) and COL2A1
(600-fold, p <0.0001) Fig. 3d.
PCR array
The mRNA expression of 84 genes involved in the move-
ment of cells including growth factors and receptors im-
portant for chemotaxis, genes involved in Rho family
signaling and adhesion, and genes encoding components
of various cellular projections was quantified with Human
Cell Motility RT2 Profiler™ PCR Array (Fig. 3b).
Fig. 2 Chondrocyte migration experiment results (n = 4). a Scratch assay measuring the distance between the wound migration fronts in a
chondrocyte monolayer and b wound closure rate in a chondrocyte monolayer scratch assay at the 3-h time point. c Representative image of
xCELLigence cell migration analysis from four wells (technical replicates) with chondrocytes measured for 3 days evaluating the chemokinetic effect of
peripheral blood mononuclear cells (PBMC+ in the lower chamber and PBMC# in the same chamber). Error bars represent standard deviation and cell
index value is based on impedance measurements that provide quantitative information about cell migration through the pores of the membrane
measured continuously with microelectrodes. d Total chondrocyte migration at day 3 in the xCELLigence assay and e xCELLigence assay comparing
mesenchymal stroma cell (MSC) and chondrocyte (CHO) migration at day 3 (n = 6). f Total cartilage cell migration from tissue explant at day 28 in the
xCELLigence assay. g Cartilage cell migration rate from tissue explant at day 14 in the xCELLigence assay. **p <0.001, ***p <0.0001 and ****p <0.00001
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Fig. 3 a Cell proliferation measured with CyQUANT total DNA assay (n = 5) showing non-significant difference between the test groups. b PCR
array results showing a change in mRNA levels after 24 h peripheral blood mononuclear cell (PBMC) stimulation with a cutoff value of 4. Heat
map visualization of 2log2 fold change of the 84 genes in the human cell motility array (red upregulated and green downregulated). Grey shows
the genes that were undetermined (no Ct value with a cutoff value of 35). c Scatterplot shows up- and down regulated genes and core genes
with no change (biological n = 5). d Messenger RNA fold change of Collagen type II and Sox9 after 24 h PBMC stimulation (n = 5) p <0.00001. All
data normalized to B2M housekeeping gene and unstimulated control. In every mRNA expression study chondrocytes in passage 3 were used
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lation (n = 5); matrix metalloproteinase (MMP)9 (29.1-
fold change), integrin (ITGβ)3 (2.2-fold change), IGF1
(5.8-fold change) and phospholipase D1 (PLD1) (9.2-fold
change). Three genes were significantly downregulated
(n = 5);MYL9 (−2.6-fold change), PAK1 (−2.2-fold change)
and CAPN2 (−2.6-fold change) by the 24 h PBMC stimula-
tion as compared to the unstimulated test group (Fig. 3c).
The upregulation of MMP9 and IGF1 was additionally
validated with qPCR (data not shown).Discussion
The migration potential of cells is considered important
for their integration into host tissue during healing and
repair processes as well as for their therapeutic applica-
tions. In this study, we have demonstrated that the addition
of PBMCs has a profound effect on chondrocyte migration,
possibly via MMP9 and/or IGF1 mechanisms. In order for
a cartilage defect to heal, one key aspect is that the cells
that will infill the damaged tissue must migrate to and pro-
liferate at the site of damage. Despite some cell migration
potential from cartilage tissue in young experimental ani-
mals [32, 33], there is a lack of evidence for chondrogenic
cells infiltrating from cartilage tissue into existing defects
and even to occupy empty chondrocyte lacunae [34, 35].It is believed that chondrocytes in adult cartilage do
not migrate due to the surrounding highly tensile colla-
gen network resulting in a highly pressurized matrix [4],
essentially trapping the cells within the ECM. However,
a small number of publications do describe chondrocyte
migration in physically damaged tissue [5, 6] or enzymati-
cally degraded matrix [10, 13, 36, 37]. Previous studies
have described progenitor cells found in cartilage explants
[10, 38, 39] where cells have been allowed to migrate from
cut pieces of tissue out onto plastic surfaces. This method
may be less damaging to the cells when compared to en-
zymatic digestion but the impact of differences that the
isolation method has on the resultant cell population
phenotype is yet not fully understood [39–42]. Enzymatic
digestion may negatively affect cellular properties, due to
a major alteration of the natural environment of the cells
and the removal of cell surface proteins [42, 43]. Our
study confirms these observations and we have attempted
to minimise any potential cartilage damage by only using
macroscopically normal cartilage and preparing the ex-
plants using a biopsy punch. However, although stimu-
lation of cell migration by both explant construction
and the presence of OA in the joint cannot be ruled
out in our study, any clinical application for PBMCs is
likely to involve similarly diseased and/or physically
damaged tissue.
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and direct cell-to-cell contact models, enhancement of
chondrocyte migration by PBMC was studied in both a
scratch assay and a Boyden chamber model. Our initial
observations were that in the scratch assay (direct cell-
to-cell contact), there was a significant increase in chon-
drocyte migration in response to PBMC. Measurements
of total DNA in the scratch assay indicated that this ob-
served effect was not due to cell proliferation but was a
genuine migration phenomenon. PCR analysis of two key
cartilage-related genes (Collagen type II and Sox9) con-
firmed that these cells were retaining their chondrogenic
phenotype and not differentiating towards a more fibro-
blastic phenotype despite their migratory ability.
To further evaluate the effects of PBMC on chondro-
cyte migration a Boyden chamber model was used, in
which PBMCs could be used to stimulate chondrocytes
directly and indirectly. The results show that the total
number of migrating chondrocytes was increased both
when PBMCs were in direct (8.2 × migration compared to
control) and indirect contact (9.7 × migration compared
to control). These values are very similar and, indicate that
for isolated chondrocytes the physical presence of the
PBMC is not the key signalling component of the re-
sponse and that a secreted factor(s) are likely to be driving
the increase in chondrocyte migration.
In contrast, when chondrocytes remained within the
cartilage explant, significant cell migration was only de-
tected when the PBMCs were in direct contact with the
tissue, with little cell migration seen when the PBMCs
were indirectly stimulating the tissue, indicating that
direct cell-cell interactions were required to promote mi-
gration. The tissue explant model is a better representation
of the clinical situation because enzymatically digested
chondrocytes in culture have possibly changed their cell
surface protein receptors, lost their native conformation
together with the extra cellular matrix and they are known
to dedifferentiate in a monolayer culture. The extra cellular
matrix itself presents a physical barrier for some of the sig-
nalling molecules which might explain to some extent the
differences in the results comparing the cell migration be-
tween chondrocyte culture and cartilage explant in this
study. In native environments, cells often navigate in the
context of multiple simultaneously presented cues where
the ECM environment adds further complexity that could
provide conflicting signals to migrating cells if it is not co-
ordinated with chemical gradients [44, 45].
Experiments in young animals have shown that chon-
drocyte migration affects tissue-engineered cartilage in-
tegration by activating the signal transduction pathways
involving Src, PLCγ1, and ERK1/2 [46]. In order to begin
to investigate the mechanisms underlying the promotion
of migration by PBMC in adult OA cartilage, we performed
gene array analysis using a human cell motility PCR array.This revealed that the mRNA levels of four genes (ITGB3,
IGF1, PLD1 and MMP9) were significantly upregulated by
the 24-h PBMC stimulation in the PBMC/chondrocyte co-
culture as compared to the unstimulated test group. Of
these genes, MMP9 (gelatinase B) is an interesting candi-
date as a key chondrocyte migration regulator. MMP9 is
capable of degrading some components of the ECM and
would, in intact cartilage, allow cell migration to occur
through the ECM [47]. However, in our study using iso-
lated chondrocytes there is no established ECM to be de-
graded so a proteolytic role for MMP9 is unlikely. In
support of our study, it has been reported that MMP9 has
a direct paracrine interaction with chondrocytes and leuko-
cytes and this finding could indicate the mechanism for
the upregulation of migration by PBMCs [48].
Chondrocyte responses to monocyte/macrophage signals
are well described. They lead to catabolic activities of cartil-
age cells and, thus, contribute to the creation of chronic
inflammatory joint disease [49–51]. These catabolic activ-
ities are known to increase the secretion of catabolic pro-
enzymes such as MMPs and their activated forms. If
MMP9 enhances uncontrolled cell migration and acceler-
ates tissue disruption in OA, blocking cell migration might
delay degeneration. On the other hand, if the migrating
cells function in tissue rebuilding, cell migration should be
promoted [8]. Understanding the function of the migratory
cartilage cells in vivo at different stages of disease is critical
when designing therapies to regenerate the damaged tissue.
Chondrocyte migration has been previously shown to
be controlled additionally by growth factors and cytokines.
FGF2, IGF1 and PDGF have been shown to promote migra-
tion, whilst BMP2, IL1β and TNFα have been shown to in-
hibit this process [15, 52]. In our study PBMC stimulus
demonstrated significant upregulation of IGF1 in human
chondrocytes. IGF1 is an established chondrogenic factor
and we have also demonstrated its efficacy in potential re-
generative cartilage models demonstrating increases in cell
number and ECM deposition within biomimetic scaffolds
[53, 54]. IGF1 is also reported to have anti-apoptotic activity
in cartilage [55] in addition to triggering chondrocyte mi-
tosis [56]. The population of migratory cells in human ar-
ticular cartilage tissue have been reported and termed as
chondrogenic progenitor cells [57]. These migratory cells
from repair tissue have been identified during the later
stages of human OA and these cells exhibit stem cell char-
acteristics such as clonogenicity, multipotency and migra-
tory activity [57]. These progenitor cells are exciting targets
for cell-based regenerative therapy for joint diseases [58]
and in the future it would be interesting to evaluate the ef-
fect of PBMC stimulation on chondrogenic progenitor cells.
Conclusions
The results of this study demonstrate that the presence
of PBMCs induces cell migration from articular cartilage
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drocytes and the rate of cell movement. This study
identifies MMP9 and IGF1 as possible regulators for the
PBMC-stimulated chondrocyte migration. This novel and
encouraging finding both challenges our basic understand-
ing of chondrocyte biology and presents an opportunity
for clinical translation. PBMCs are a readily available cell
source capable of providing signaling molecules that stimu-
late chondrocyte motility. Thus, autologous PBMCs could
be utilized in a point-of-care treatment to attract native
chondrocytes or chondrogenic progenitor cells from the af-
fected tissue to aid in cartilage repair via single or multiple
PBMC intra-articular injections.
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